S
Sushama Talegaonkar
Researcher at Delhi Institute of Pharmaceutical Sciences and Research
Publications - 180
Citations - 6764
Sushama Talegaonkar is an academic researcher from Delhi Institute of Pharmaceutical Sciences and Research. The author has contributed to research in topics: Drug delivery & Bioavailability. The author has an hindex of 39, co-authored 171 publications receiving 5311 citations. Previous affiliations of Sushama Talegaonkar include Hamdard University & Jamia Hamdard.
Papers
More filters
Journal ArticleDOI
Zinc oxide nanoparticles: a promising nanomaterial for biomedical applications.
TL;DR: Zinc oxide NPs have been successfully exploited as drug carriers for loading and transporting drugs to target sites, thereby reducing unwanted toxicity and off-target effects, and resulting in amplified synergistic effects.
Journal ArticleDOI
Nanoemulsion Components Screening and Selection: a Technical Note
Adnan Azeem,Mohammad Rizwan,Farhan Jalees Ahmad,Zeenat Iqbal,Roop K. Khar,Mohd. Aqil,Sushama Talegaonkar +6 more
TL;DR: The main objective of this study was to provide an efficient screening approach for the proper selection of oils, surfactants, and cosurfactants for the nanoemulsion formulation development.
Journal ArticleDOI
Microemulsions: a novel approach to enhanced drug delivery.
Sushama Talegaonkar,Adnan Azeem,Farhan Jalees Ahmad,Roop K. Khar,Shadab A. Pathan,Zeenat I. Khan +5 more
TL;DR: A critical evaluation of recent patents claiming different approaches to improve the drug delivery is the focus of the current review.
Journal ArticleDOI
Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.
TL;DR: An overview of the investigations on the feasibility and application of flavonoids as P-gp modulators for improved efficacy of anti-cancer drugs like taxanes, anthracyclines, epipodophyllotoxins, camptothecins and vinca alkaloids is presented.
Journal ArticleDOI
Vesicular systems: An overview
TL;DR: The focus of this review is to bring out the application, advantages, and drawbacks of vesicular systems, which can be predicted to prolong the existence of the drug in systemic circulation, and reduce the toxicity.